Residency · Residency · Medicine-Pediatrics
Venous Thromboembolism: Age-Specific Risk and Management
Overview
Venous thromboembolism (VTE) includes deep vein thrombosis (DVT) and pulmonary embolism (PE) VTE is common in adults (1-2 per 1,000/year) but rare in children (~0.07-0.14 per 10,000/year) Pediatric VTE incidence is rising due to increased survival of critically ill children, central venous catheter use, and childhood obesity. Bimodal pediatric distribution: neonates and adolescents. Management principles differ substantially between children and adults.
Risk Factors
Pediatric Risk Factors
Central venous catheters: single greatest risk factor, present in >90% of neonatal and >50% of childhood VTE. Congenital heart disease and cardiac surgery; Cancer and chemotherapy (especially asparaginase); Infection/sepsis; Nephrotic syndrome (urinary loss of antithrombin); Dehydration (especially in neonates — renal vein thrombosis, cerebral venous sinus thrombosis) Immobilization, trauma, surgery; Obesity (emerging risk factor); Oral contraceptive use in adolescents; Inherited thrombophilia (lower contribution than in adults).
Adult Risk Factors
Surgery (especially orthopedic, cancer surgery), immobilization, hospitalization. Active malignancy (Trousseau syndrome); Oral contraceptives and hormone replacement therapy; Pregnancy and postpartum period; Obesity, age >60; Prior VTE (strongest predictor of recurrence); Inherited thrombophilia: Factor V Leiden, prothrombin G20210A mutation, protein C/S deficiency, antithrombin deficiency. Acquired: antiphospholipid syndrome, myeloproliferative neoplasms.
<image>Comparison of VTE risk factors in pediatric versus adult populations showing relative contribution of central venous catheters, immobilization, thrombophilia, and hormonal factors by age group</image>
Clinical Presentation
DVT
Children: upper extremity DVT more common than lower extremity (reflects CVC-related disease); may present with limb swelling, pain, collateral vein distension, or catheter malfunction. Adults: lower extremity DVT predominates (especially left leg — May-Thurner anatomy); calf pain, swelling, warmth, Homan sign (unreliable) Neonates: renal vein thrombosis (hematuria, flank mass, thrombocytopenia), portal vein thrombosis, cerebral venous sinus thrombosis.
Pulmonary Embolism
Adults: dyspnea, pleuritic chest pain, tachycardia, hemoptysis; massive PE presents with hypotension/shock. Children: PE is likely underdiagnosed; presentation is often nonspecific (tachypnea, chest pain, hypoxia) Adolescents on OCPs with unexplained dyspnea should prompt PE consideration.
Diagnosis
Adult VTE Diagnosis
Clinical probability scores: Wells score for DVT and PE; Geneva score for PE. D-dimer: high negative predictive value in low-probability patients; age-adjusted cutoff (age x 10 for patients >50) improves specificity. Compression ultrasonography: first-line for DVT (sensitivity >95% for proximal DVT) CT pulmonary angiography (CTPA): gold standard for PE diagnosis. V/Q scan: alternative when CTPA contraindicated (contrast allergy, renal insufficiency, pregnancy consideration)
Pediatric VTE Diagnosis
Clinical probability scores are NOT validated in children. D-dimer: less useful; normal values differ by age; false positives common in neonates and infants. Ultrasound: first-line for DVT; technically challenging in small children. CTPA: used for PE but radiation exposure is a concern; balance with clinical urgency. MR venography: useful for central venous thrombosis without radiation. Echocardiography: for right heart thrombus, especially in neonates with CVC-related thrombosis.
Anticoagulation: Pediatric Versus Adult
Unfractionated Heparin (UFH)
Neonates and infants require higher weight-based doses due to lower antithrombin levels and larger volume of distribution. Pediatric loading dose: 75 U/kg bolus, then 28 U/kg/hr (infants) or 20 U/kg/hr (children >1 year) Adult: 80 U/kg bolus, then 18 U/kg/hr. Monitor with anti-Xa (preferred) or aPTT. Antithrombin supplementation may be needed in neonates who are heparin-resistant.
Low-Molecular-Weight Heparin (LMWH)
| Population | Enoxaparin Treatment Dose | Monitoring |
|---|---|---|
| Infants <2 months | 1.5 mg/kg/dose q12h | Anti-Xa levels (target 0.5-1.0 U/mL) |
| Children >2 months | 1 mg/kg/dose q12h | Anti-Xa levels (target 0.5-1.0 U/mL) |
| Adults | 1 mg/kg q12h or 1.5 mg/kg daily | Anti-Xa levels if extremes of weight/renal insufficiency |
Enoxaparin is the most studied LMWH in pediatrics. More predictable pharmacokinetics than UFH; preferred for outpatient management.
Direct Oral Anticoagulants (DOACs)
Rivaroxaban: approved for children >= 2 years for VTE treatment (based on EINSTEIN-Jr trial) Dosing is weight-based in children with special pediatric formulations. Adult: rivaroxaban 15 mg BID x 21 days then 20 mg daily; apixaban 10 mg BID x 7 days then 5 mg BID. DOACs do NOT require routine monitoring; no reliable reversal for some agents (andexanet alfa for factor Xa inhibitors) Dabigatran: approved for children >= 3 months (post-heparin treatment)
Warfarin
Previously the mainstay for long-term anticoagulation in children; now increasingly replaced by DOACs and LMWH. Challenging in children: breast milk and formula vitamin K content varies, frequent dose adjustments, dietary changes. Neonates have naturally low vitamin K-dependent factors — very sensitive to warfarin. INR target: 2.0-3.0 for most indications (same as adults) Adults: still used for mechanical heart valves, antiphospholipid syndrome, and patient/cost preference.
<image>Weight-based dosing comparison table for anticoagulants across age groups showing UFH, LMWH, rivaroxaban, and dabigatran with pediatric versus adult dosing and monitoring parameters</image>
Duration of Therapy
Pediatric Guidelines (CHEST/ASH)
CVC-related DVT: 6 weeks to 3 months (remove or replace catheter if possible); Provoked VTE (non-CVC): 3 months minimum; Unprovoked VTE: 6-12 months; Recurrent unprovoked VTE: consider extended anticoagulation; Neonatal renal vein thrombosis: 6 weeks to 3 months.
Adult Guidelines
Provoked by transient risk factor (surgery, immobilization): 3 months. Provoked by ongoing risk factor (active cancer): extended until risk resolves; LMWH or DOACs preferred for cancer-associated VTE. Unprovoked first VTE: at least 3 months, then reassess; consider extended if low bleeding risk (especially in males, elevated D-dimer after stopping, proximal DVT) Recurrent unprovoked: indefinite anticoagulation.
Thrombophilia Testing
When to Test
Not recommended routinely after provoked VTE in either children or adults; Consider in:; Unprovoked VTE in young adults or children; Family history of VTE, especially in first-degree relatives <50 years; Recurrent VTE; Unusual site thrombosis (cerebral, portal, mesenteric veins); Neonatal purpura fulminans (suspect severe protein C or S deficiency).
What to Test
Factor V Leiden mutation, prothrombin G20210A mutation. Protein C, protein S, antithrombin III activity. Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-beta-2 glycoprotein) Homocysteine level. Timing: test BEFORE starting anticoagulation or >2 weeks after completion (warfarin lowers protein C/S; heparin lowers antithrombin; acute thrombosis affects all levels)
<image>Flowchart for thrombophilia testing decisions showing indications, timing relative to anticoagulation therapy, and interpretation of results in the context of pediatric versus adult VTE</image>
VTE Prophylaxis
Pediatric Prophylaxis
No universally accepted risk assessment model (unlike adults) Consider prophylaxis for: immobilized adolescents post-surgery, adolescents with multiple risk factors, cancer patients with CVC. LMWH at prophylactic doses: enoxaparin 0.5 mg/kg every 12 hours (children) Mechanical prophylaxis (graduated compression stockings, pneumatic compression): limited pediatric data but used empirically.
Adult Prophylaxis
Well-established guidelines (Padua score for medical, Caprini score for surgical) Pharmacologic: LMWH, UFH, or fondaparinux for hospitalized medical and surgical patients at moderate-high risk. Mechanical: sequential compression devices for low-risk or in addition to pharmacologic. Extended prophylaxis post-discharge: consider for high-risk cancer surgery (28 days) and hip/knee arthroplasty (35 days)
Special Populations
Neonatal VTE
Most common in neonatal ICU with central lines. Renal vein thrombosis: associated with dehydration, perinatal asphyxia, maternal diabetes. Cerebral venous sinus thrombosis: may present with seizures. Treatment: LMWH or UFH; warfarin extremely difficult to manage in neonates. Thrombolysis reserved for life- or organ-threatening thrombosis.
Cancer-Associated VTE
In adults, DOACs (edoxaban, rivaroxaban, apixaban) have largely replaced LMWH for non-GI cancers. GI cancers: higher GI bleeding risk with DOACs; LMWH may still be preferred. In children with cancer: LMWH remains standard; DOACs emerging but less studied in pediatric oncology.
Clinical Pearls
Upper extremity DVT in children is almost always CVC-related; in adults, consider Paget-Schroetter syndrome (effort thrombosis) or thoracic outlet syndrome. Neonatal purpura fulminans with DIC should prompt urgent testing for homozygous protein C or S deficiency — treat with protein C concentrate or FFP. DOACs have transformed pediatric VTE management but pediatric formulations (suspensions) must be used — adult tablets cannot simply be cut for smaller doses. In adolescent females on OCPs who develop VTE, discontinue hormonal contraception and offer non-estrogen alternatives (IUD, progestin-only) Post-thrombotic syndrome (chronic venous insufficiency, pain, swelling) occurs in 10-60% of children after DVT; compression stockings may reduce risk. Always consider antiphospholipid syndrome in young adults with unprovoked VTE, especially with concurrent thrombocytopenia or pregnancy complications.
References
- Monagle P, Cuello CA, Augustine C, et al. American Society of Hematology 2018 Guidelines for Management of Venous Thromboembolism: Treatment of Pediatric Venous Thromboembolism. Blood Adv. 2018;2(22):3292-3316.
- Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-352.
- Albisetti M, Moeller A, Engel H, et al. Evaluation of Rivaroxaban for the Treatment of Venous Thromboembolism in Children (EINSTEIN-Jr). Blood. 2020;136(Suppl 1):34-35.
- Mahajerin A, Croteau SE. Epidemiology and Risk Assessment of Pediatric Venous Thromboembolism. Front Pediatr. 2017;5:68.
How to think about this
Venous thromboembolism (VTE) is a critical diagnosis in both pediatric and adult populations, but the approach to diagnosis and management is nuanced and age-dependent. The underlying risk factors, typical presentation, diagnostic algorithms, and treatment strategies diverge significantly. In children, central venous catheters are overwhelmingly the primary driver, leading to a higher incidence of upper extremity deep vein thrombosis (DVT) and unique presentations like renal vein thrombosis in neonates. Adults, conversely, often present with lower extremity DVT associated with surgery, immobility, or malignancy. While clinical probability scores and D-dimer tests are cornerstones of adult diagnosis, they are not validated in pediatrics, necessitating a different diagnostic pathway. Treatment also differs, with pediatric dosing of anticoagulants often higher on a weight-based scale, reflecting physiological differences. Direct Oral Anticoagulants (DOACs) are becoming more prevalent in both groups but require careful consideration of age-specific formulations and monitoring.
Check yourself with 2 bullets.
- Do you know why a neonate might require a higher weight-based dose of unfractionated heparin compared to an adult?
- Can you name one reason why D-dimer is less useful in diagnosing VTE in children compared to adults?
